CDKN2A and oropharynx cancer: In a comparable study design, the De-ESCALaTE HPV trial assigned a total of 334 patients with locally advanced low-risk p16+ oropharyngeal cancer to either radiotherapy plus cetuximab or radiotherapy plus cisplatin as primary treatment.